Transforming growth factor-alpha (TGF-a) is synthesized by a variety of tumor cell lines and stimulates osteoclastic bone resorption in vitro. The mechanism by which TGF-a increases osteoclast activity is unknown. We used a human marrow culture system that forms osteoclast-like multinucleated cells (MNCs) to determine the effects of recombinant human TGF-a on MNC formation. Addition of 0.01 ng/ml TGF-a for the 1st week followed by 1,25-dihydroxyvitamin D3 I1,25(0H)2D31 for the subsequent 2 wk significantly increased MNCs. Treatment of these cultures with TGF-a without later addition of 1,25(0H)2D3 did not increase MNC formation. Autoradiographic studies revealed that TGF-a stimulated proliferation of precursors for MNCs, and 1,25(OH)2D3 increased their rate of fusion into MNCs. Addition of murine epidermal growth factor (EGF) (0.1 ng/ml) followed by 1,25(OH)2D3 also significantly stimulated MNC formation. These data suggest that TGF-a and EGF may stimulate bone resorption by increasing the proliferation of osteoclast precursors, which leads to increased numbers of osteoclasts.
Introduction
Transforming growth factors are a heterogeneous family of polypeptides that reversibly induce anchorage-independent growth in nonneoplastic anchorage-dependent cells (1) . One group, defined as a-type, or transforming growth factor-alpha (TGF-a),' competes with epidermal growth factor (EGF) for binding to the same receptor and induces several known biological effects of EGF (2) . TGF-a was first demonstrated in the conditioned medium of virally transformed neoplastic mouse cells (3) , and has been purified from virally transformed rat cells and from human melanoma cell lines (4, 5) . Recent developments have led to the cloning of a sequence coding for both human (6) and rat (7) TGF-a, and to the production of a biologically active human TGF-a in Escherichia coli (6) . Specific hybridizations have indicated that TGF-a messenger RNA (mRNA) is present in a variety of tumors, many of which can cause malignancy-associated hypercalcemia (Derynck, R., unpublished results).
Recently, both synthetic rat (8) and recombinant human TGF-a have stimulated osteoclastic bone resorption in vitro (9-1 1). Attention, therefore, has been focused on TGF-a as a possible mediator of increased bone resorption in the humoral hypercalcemia of malignancy (12) (13) (14) (15) . However, the underlying mechanism responsible for TGF-a-induced osteoclastic bone resorption is unknown.
We recently developed a system for examining formation of osteoclast-like multinucleated cells (MNCs) from feline (16) , baboon (17) , and human bone marrow cells (MacDonald, B. R., N. Takahashi, L. M. McManus, G. R. Mundy, and G. D. Roodman, submitted for publication) in long-term cultures. The formation of MNCs was increased by parathyroid hormone and 1,25-dihydroxyvitamin D3 [1 ,25(OH)2D3] and decreased by calcitonin. The MNCs contained a tartrate-resistant acid phosphatase, which is a marker enzyme for osteoclasts whose activity was modulated appropriately by osteotropic hormones (16, 17) .
In this report, we examined the effects ofrecombinant human TGF-a and purified murine EGF on the MNC formation in human marrow long-term culture. We now report that TGF-a stimulates the formation of MNCs with osteoclast-like characteristics by increasing the proliferation of the precursors for these cells.
Methods
Collection and culture ofhuman marrow cells. After obtaining informed consent, bone marrow was aspirated from the iliac crest ofhealthy normal donors. Marrow aspirates were collected in syringes containing 1,000 U/ml preservative-free heparin (Sigma Chemical Co., St. Louis, MO) in alpha minimum essential medium (MEM) (Gibco, Grand Island, NY). Marrow mononuclear cells were obtained by centrifigation on HypaqueFicoll gradients as described previously (17) . The 
Results
The effects of recombinant human TGF-a on formation of osteoclast-like MNC are shown in Table I . As we have previously reported, treatment of marrow cells with 1,25(OH)2D3 (10-8 M) for 3 wk markedly increased the number of MNCs (Table I) . Treatment ofthe cultures for only the last 2 wk with 1,25(OH)2D3 significantly increased MNC formation in two of three experiments. Addition of0.1 ng/ml TGF-a to the cultures for the first week or for all three weeks ofculture did not significantly increase the number of MNCs. However, addition of TGF-a for the first week followed by treatment with 10-8 M 1,25(OH)2D3 for the last two weeks of culture significantly increased the number of MNCs compared with corresponding control cultures treated with 1,25(OH)2D3 alone for the last two weeks (P < 0.01) ( Table I ).
The effects of adding varying concentrations of TGF-a to the cultures for 1 wk followed by 1,25(OH)2D3 (10-8 M) for the final 2 wk of culture are shown in Table II . Addition of TGF-a at 0.001-10 ng/ml to the culture for 3 wk did not change basal MNC formation (data not shown). Treatment of cultures with TGF-ax at concentrations as low as 0.01 ng/ml for the first week followed by treatment with 1,25(QH)2D3 (10-8 M) for the subsequent two weeks significantly increased the number ofMNCs. Maximal MNC formation occurred in two ofthree experiments when 0.1 ng/ml TGF-a was added to the cultures (Table II) . The total number of adherent cells per culture was not changed by treatment of the cultures with TGF-a (control = 6,996±523 adherent cells; 0.1 ng/ml TGF-a = 6,831±396 adherent cells). Because the biological effects ofTGF-a are mediated through EGF receptors, and EGF also stimulates osteoclastic bone resorption (20, 21), we next examined the effects ofEGF on MNC formation (Table III) . Addition of EGF alone (0.01-50 ng/ml) to the cultures for 3 wk did not increase the number of MNCs formed (data not shown). Treatment of marrow cells with EGF (0.1-50 ng/ml) for the first week followed by 1,25(OH)2D3 (1O-a M) for the last two weeks significantly stimulated MNC formation (Table III) . Maximal MNC formation in response to EGF was observed at concentrations of 10 ng/ml. Treatment of the cultures with EGF did not change the total number of adherent cells per culture after 3 wk of culture (control = 9,372±1,650 adherent cells; 10 ng/ml EGF = 9,240+1,056 adherent cells). In contrast to TGF-a and EGF, addition of other growth factors such as fibroblast growth factor (0.5-50 ng/ml, Collaborative Research, Inc.), platelet-derived growth factor (0.1-10 ng/ml, Collaborative Research, Inc.), or recombinant human insulinlike growth factor (0.25-25 nM, Amgen Biologicals, Thousand Oaks, CA) to the cultures for the first week followed by 1,25(OH)2D3 at 10-8 M for the next two weeks failed to stimulate MNC formation (data not shown).
Autoradiographic studies (Table IV) showed that treatment of cultures with 1,25(OH)2D3 (10-8 M) for the last 2 wk did not significantly increase the number of MNC formed on coverslips or the percentage ofMNCs containing labeled nuclei. However, this treatment significantly increased the number of labeled nuclei in MNCs containing at least one labeled nucleus. Treatment of cultures with TGF-a (0.1 ng/ml) alone for the first week did not affect these parameters. Addition ofTGF-a for the first week followed by 1,25(OH)2D3 for the next two weeks markedly increased the number of MNCs on the coverslips as well as the percentage of MNCs containing labeled nuclei. In separate experiments, treatment of cultures with 1 ,25(OH)2D3 alone for all three weeks significantly increased the number of MNCs on coverslips but did not change the percentage ofMNCs containing labeled nuclei (unpublished results). These results suggest that TGF-a stimulates the proliferation of precursors for the MNCs and 1,25(OH)2D3 increases the rate of fusion of the precursors into MNCs. EGF (10 ng/ml) stimulated MNC formation in a similar manner as TGF-a (Table IV) . Similar results were seen in two other separate experiments.
Finally, we examined whether TGF-a preparations possessed granulocyte-macrophage colony stimulating factor (CSF-GM) activity because our previous studies showed that CSF-GM increased MNC formation when CSF-GM was added for the first week of culture followed by 1,25(OH)2D3 for the last two weeks of culture (22) . In a standard marrow culture CSF assay, PCM at the concentrations of 1 or 10% markedly increased the number of colonies at 7 and 14 d of culture (Table V) . TGF-a at 0.001- In this report, we demonstrated that recombinant human TGF-a increased the number of osteoclast-like MNCs in longterm human marrow cultures when marrow cells were incubated with TGF-a for the first week followed by 1,25(OH)2D3 for two weeks. Autoradiographic studies demonstrated that TGF-a stimulated the proliferation of precursors of MNCs while 1,25(OH)2D3 stimulated the fusion of these precursors into MNCs. We previously reported that CSF increases the number of MNCs by stimulating proliferation ofthe precursors for these cells in baboon marrow cultures, and 1,25(OH)2D3 potentiated CSF effects by promoting fusion of the precursors (22) . Thus, the action of TGF-a on MNC formation is similar to that of CSF. TGF-a, however, had no CSF-like activity in a standard marrow culture CSF assay. This indicates that both TGF-a and CSF are able to enhance the proliferation of precursors for osteoclast-like cells. Possibly the action ofTGF-a may be restricted to a committed osteoclast precursor, which may be a more differentiated progeny ofCFU-GM, while CSF is acting on the less differentiated CFU-GM. In contrast to TGF-a and CSF, other growth factors such as fibroblast growth factor, platelet-derived growth factor, and insulinlike growth factor failed to stimulate MNC formation. This suggests that although these growth factors are mitogenic for many cell types, the stimulation of MNC formation appears to be a specific property of TGF-a and CSF.
EGF is known to be a potent stimulant of osteoclastic bone resorption (20, 21). In our experiments, EGF increased the number of osteoclast-like cells similar to TGF-a. These results suggest that the bone-resorbing activity of EGF may result in part from the enhancement of proliferation of osteoclast precursors.
TGF-a has recently been implicated in the pathogenesis of the humoral hypercalcemia of malignancy (14, 15) . This syndrome is thought to be caused by tumor cells releasing circulating factors that stimulate osteoclastic bone resorption (14, 15, 23) . Ibbotson et al. (12) first demonstrated that in the hypercalcemic variant of the rat Leydig cell tumor, TGF-a-like activity was produced by the tumor cells and stimulated bone resorption in organ culture. The tumor-derived bone-resorbing activity was blocked by antisera to the EGF receptor (13) . In addition, both synthetic rat (8) and recombinant-human TGF-a have been shown to stimulate bone resorption in vitro (9-1 1). These observations indicate that TGF-a may be responsible for increased bone destruction in some neoplastic disease states.
Although many lines of evidence indicate that TGF-a is a tumor product in adult animal and human, TGF-a has also been found in increased amounts in developing rodent embryos (24) . Recently, Smith et al. (25) reported that TGF-a accelerated eyelid opening on newborn mice and Tam (26) showed that TGF-a also accelerated incisor eruption in these animals. These results suggest that TGF-a could have physiological actions in the developing fetus and newborns. The effects of TGF-a on bone resorption and on the formation of osteoclast-like cells support the conclusion that TGF-a could play an important role in bone metabolism in both normal and pathologic states by stimulating the proliferation of osteoclast precursors. These results further suggest that the precursors for osteoclast-like cells are exquisitely sensitive to TGF-a and respond to TGF-a at much lower concentrations than those reported in other systems (8) (9) (10) (11) (12) .
